Literature DB >> 26603238

PROTECTIVE LEVELS OF VARICELLA-ZOSTER ANTIBODY DID NOT EFFECTIVELY PREVENT CHICKENPOX IN AN X-LINKED AGAMMAGLOBULINEMIA PATIENT.

Fernanda Aimée Nobre1, Isabela Garrido da Silva Gonzalez1, Maria Isabel de Moraes-Pinto1, Beatriz Tavares Costa-Carvalho1.   

Abstract

We describe the case of an eight-year-old boy with X-linked agammaglobulinemia who developed mild varicella despite regular intravenous immunoglobulin (IVIG) therapy. He maintained protective antibody levels against varicella and the previous batches of IVIG that he received had adequate varicella-specific IgG levels. The case illustrates that IVIG may not prevent VZV infection.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26603238      PMCID： PMC4660460          DOI： 10.1590/S0036-46652015000500017

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN： 0036-4665            Impact factor:   1.846


  17 in total

1.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

2.  Measles-virus-neutralizing antibodies in intravenous immunoglobulins.

Authors:  Susette Audet; Maria Luisa Virata-Theimer; Judy A Beeler; Dorothy E Scott; Douglas J Frazier; Malgorzata G Mikolajczyk; Nancy Eller; Feng-ming Chen; Mei-ying W Yu
Journal:  J Infect Dis       Date:  2006-08-16       Impact factor: 5.226

Review 3.  Differences between IGIV products: impact on clinical outcome.

Authors:  Erwin W Gelfand
Journal:  Int Immunopharmacol       Date:  2005-12-06       Impact factor: 4.932

Review 4.  Booster vaccinations: can immunologic memory outpace disease pathogenesis?

Authors:  Michael E Pichichero
Journal:  Pediatrics       Date:  2009-11-23       Impact factor: 7.124

Review 5.  Advances in the understanding of the pathogenesis and epidemiology of herpes zoster.

Authors:  Anne A Gershon; Michael D Gershon; Judith Breuer; Myron J Levin; Anne Louise Oaklander; Paul D Griffiths
Journal:  J Clin Virol       Date:  2010-05       Impact factor: 3.168

6.  European seroepidemiology network 2: Standardisation of assays for seroepidemiology of varicella zoster virus.

Authors:  Fernando de Ory; José Manuel Echevarría; George Kafatos; Cleo Anastassopoulou; Nick Andrews; Josephine Backhouse; Guy Berbers; Blazena Bruckova; Daniel I Cohen; Hester de Melker; Irja Davidkin; Giovanni Gabutti; Louise M Hesketh; Kari Johansen; Sari Jokinen; Lindsay Jones; Anika Linde; Elisabeth Miller; Joël Mossong; Anthony Nardone; Maria Cristina Rota; Andreas Sauerbrei; François Schneider; Zahava Smetana; Annedore Tischer; Athanassios Tsakris; Robert Vranckx
Journal:  J Clin Virol       Date:  2006-04-17       Impact factor: 3.168

7.  The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.

Authors:  S Mankarious; M Lee; S Fischer; K H Pyun; H D Ochs; V A Oxelius; R J Wedgwood
Journal:  J Lab Clin Med       Date:  1988-11

8.  Varicella-specific immunoglobulin G titers in commercial intravenous immunoglobulin preparations.

Authors:  Ashley M Maranich; Michael Rajnik
Journal:  Pediatrics       Date:  2009-08-17       Impact factor: 7.124

Review 9.  Primary immunodeficiencies.

Authors:  Luigi D Notarangelo
Journal:  J Allergy Clin Immunol       Date:  2009-12-29       Impact factor: 10.793

Review 10.  Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency.

Authors:  Melvin Berger
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479
View more
  2 in total

1.  Low Rates of Poliovirus Antibodies in Primary Immunodeficiency Patients on Regular Intravenous Immunoglobulin Treatment.

Authors:  Beatriz T Costa-Carvalho; Kathleen E Sullivan; Patrícia M Fontes; Fernanda Aimé-Nobre; Isabela G S Gonzales; Elaine S Lima; Celso Granato; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2018-07-14       Impact factor: 8.317

2.  Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans.

Authors:  Nicole L Sullivan; Morgan A Reuter-Monslow; Janet Sei; Eberhard Durr; Carl W Davis; Cathy Chang; Megan McCausland; Andreas Wieland; David Krah; Nadine Rouphael; Aneesh K Mehta; Mark J Mulligan; Bali Pulendran; Rafi Ahmed; Kalpit A Vora
Journal:  J Virol       Date:  2018-06-29       Impact factor: 6.549
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.